Last checked at 30 Dec 2020 12:50
genedrive plc
("genedrive" or the "Company")
Result of AGM
Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.
For information, details of the proxy voting are shown below:
Votes For | Vote For (as % of votes cast) | Votes Against | Votes Against (as % of votes cast) | Votes withheld | |
1 Receive the Annual report and accounts for the Company | 18,105,091 | 99.6% | 76,514 | 0.4% | 98,780 |
2 Approve the Directors Remuneration Report | 18,004,341 | 99.2% | 143,950 | 0.8% | 131,981 |
3 Re-appoint Tom Lindsay as a director | 18,046,634 | 99.4% | 105,545 | 0.6% | 128,206 |
4 Re-appoint Chris Yates as a director | 18,049,104 | 99.4% | 103,075 | 0.6% | 128,206 |
5 Re-appoint David Budd as a director | 18,020,957 | 99.2% | 148,510 | 0.8% | 110,918 |
6 Re-appoint Matthew Fowler as a director | 18,049,104 | 99.4% | 103,075 | 0.6% | 128,206 |
7 Re-appoint Ian Gilham as a director | 16,874,853 | 99.3% | 120,159 | 0.7% | 1,285,373 |
8 Re-appointment of RSM UK as auditors of the Company | 18,062,908 | 99.6% | 79,628 | 0.4% | 137,849 |
9 Directors authority to allot shares | 17,902,887 | 98.7% | 229,670 | 1.3% | 147,828 |
10 Disapplication of pre-emption rights | 16,773,042 | 92.6% | 1,341,787 | 7.4% | 165,041 |
The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO / Matthew Fowler: CFO | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
James Steel / Oliver Jackson | |
finnCap (Joint Broker) | +44 (0)20 7220 0500 |
Geoff Nash / Kate Bannatyne / Alice Lane | |
Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.